We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease
Jul 25
Hong Kong (HSI) Biotech Industry Analysis
UpdatedJul 25, 2024
DataAggregated Company Financials
Companies48
- 7D-4.5%
- 3M-8.7%
- 1Y-34.6%
- YTD-21.9%
Over the last 7 days, the Biotech industry has dropped 4.5%, driven by a pullback from Innovent Biologics of 5.2%. In contrast, Qyuns Therapeutics has gained 8.0%. The industry has fallen 35% in the last year. Earnings are forecast to grow by 34% annually.
Industry Valuation and Performance
Has the Hong Kong Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 26 Jul 2024 | HK$316.7b | HK$49.6b | -HK$19,417,178,923.93 | 11.9x | -16.3x | 6.4x |
| Sun, 23 Jun 2024 | HK$332.5b | HK$49.7b | -HK$19,449,051,702.56 | 11.4x | -17.1x | 6.7x |
| Tue, 21 May 2024 | HK$371.0b | HK$49.8b | -HK$19,367,659,887.46 | 12.2x | -19.2x | 7.5x |
| Thu, 18 Apr 2024 | HK$324.1b | HK$49.6b | -HK$19,910,867,416.24 | 10.7x | -16.3x | 6.5x |
| Sat, 16 Mar 2024 | HK$366.5b | HK$47.2b | -HK$20,336,879,317.71 | 17.6x | -18x | 7.8x |
| Mon, 12 Feb 2024 | HK$321.6b | HK$47.0b | -HK$20,274,962,687.09 | 15.5x | -15.9x | 6.8x |
| Wed, 10 Jan 2024 | HK$378.5b | HK$47.1b | -HK$20,324,950,537.00 | 17.6x | -18.6x | 8x |
| Fri, 08 Dec 2023 | HK$403.9b | HK$47.0b | -HK$20,301,292,526.00 | 17.5x | -19.9x | 8.6x |
| Sun, 05 Nov 2023 | HK$413.3b | HK$45.2b | -HK$18,919,413,159.00 | 12.9x | -21.8x | 9.2x |
| Tue, 03 Oct 2023 | HK$400.6b | HK$45.0b | -HK$19,140,443,270.00 | 13.9x | -20.9x | 8.9x |
| Thu, 31 Aug 2023 | HK$392.2b | HK$43.4b | -HK$16,560,885,846.00 | 15.1x | -23.7x | 9x |
| Sat, 29 Jul 2023 | HK$427.6b | HK$35.5b | -HK$23,368,379,129.00 | 28x | -18.3x | 12x |
| Mon, 26 Jun 2023 | HK$386.4b | HK$35.6b | -HK$23,401,635,975.00 | 24.1x | -16.5x | 10.9x |
| Wed, 24 May 2023 | HK$436.6b | HK$36.1b | -HK$23,815,835,639.00 | 30.1x | -18.3x | 12.1x |
| Fri, 21 Apr 2023 | HK$443.5b | HK$37.0b | -HK$24,172,668,230.00 | 18.6x | -18.3x | 12x |
| Sun, 19 Mar 2023 | HK$405.8b | HK$32.4b | -HK$35,522,328,250.00 | 22.9x | -11.4x | 12.5x |
| Tue, 14 Feb 2023 | HK$445.5b | HK$34.8b | -HK$35,139,835,760.00 | 31.5x | -12.7x | 12.8x |
| Thu, 12 Jan 2023 | HK$441.8b | HK$34.9b | -HK$35,233,612,905.00 | 29.6x | -12.5x | 12.7x |
| Sat, 10 Dec 2022 | HK$392.8b | HK$33.6b | -HK$33,903,437,875.00 | 24.6x | -11.6x | 11.7x |
| Mon, 07 Nov 2022 | HK$356.4b | HK$33.8b | -HK$32,491,041,863.00 | 18.5x | -11x | 10.6x |
| Wed, 05 Oct 2022 | HK$286.6b | HK$34.0b | -HK$32,534,935,782.00 | 17.3x | -8.8x | 8.4x |
| Fri, 02 Sep 2022 | HK$335.0b | HK$34.2b | -HK$33,506,026,858.00 | 15.7x | -10x | 9.8x |
| Sun, 31 Jul 2022 | HK$328.6b | HK$32.9b | -HK$46,359,653,984.00 | 13x | -7.1x | 10x |
| Tue, 28 Jun 2022 | HK$381.5b | HK$33.1b | -HK$46,719,776,226.00 | 14.7x | -8.2x | 11.5x |
| Thu, 26 May 2022 | HK$321.4b | HK$34.3b | -HK$46,256,256,982.00 | 12.8x | -6.9x | 9.4x |
| Sat, 23 Apr 2022 | HK$332.4b | HK$36.0b | -HK$45,702,949,061.00 | 12.9x | -7.3x | 9.2x |
| Mon, 21 Mar 2022 | HK$324.3b | HK$34.8b | -HK$33,336,593,534.00 | 13.2x | -9.7x | 9.3x |
| Wed, 16 Feb 2022 | HK$306.3b | HK$31.1b | -HK$31,890,332,437.00 | 12.4x | -9.6x | 9.8x |
| Fri, 14 Jan 2022 | HK$370.9b | HK$31.1b | -HK$31,849,988,407.00 | 13.4x | -11.6x | 11.9x |
| Sun, 12 Dec 2021 | HK$480.7b | HK$31.1b | -HK$31,827,233,997.00 | 13.5x | -15.1x | 15.5x |
| Tue, 09 Nov 2021 | HK$447.8b | HK$30.9b | -HK$31,620,779,940.00 | 13.8x | -14.2x | 14.5x |
| Thu, 07 Oct 2021 | HK$480.9b | HK$30.5b | -HK$31,539,898,721.00 | 15x | -15.2x | 15.8x |
| Sat, 04 Sep 2021 | HK$529.2b | HK$30.2b | -HK$32,058,827,347.35 | 17.5x | -16.5x | 17.5x |
| Mon, 02 Aug 2021 | HK$564.1b | HK$30.2b | -HK$32,058,827,347.35 | 13.6x | -17.6x | 18.7x |
Price to Earnings Ratio
-17.6x
Current Industry PE
- Investors are pessimistic on the Hong Kong Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 10.6x is higher than the industry's current PS ratio of 6.4x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have improved over the last three years.
- Revenues for these companies have grown 18% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Trends
Which industries have driven the changes within the Hong Kong Healthcare industry?
| HK Market | -1.61% | |
| Healthcare | -3.41% | |
| Biotech | -4.45% | |
| Biotech | -4.45% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 2509 Qyuns Therapeutics | HK$21.60 | 8.0% +HK$355.3m | n/a | PS302.2x | |
| 2898 Sunho Biologics | HK$6.75 | 15.2% +HK$134.1m | n/a | PS53.9x | |
| 2487 Cutia Therapeutics | HK$7.70 | 4.9% +HK$108.7m | -62.4% | PS15.8x | |
| 1672 Ascletis Pharma | HK$1.17 | 8.3% +HK$87.9m | -40.3% | PS19.3x | |
| 3681 SinoMab BioScience | HK$1.58 | 1.9% +HK$32.8m | -1.3% | PS365x |